Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
Rubius Therapeutics (Nasdaq: RUBY) announced plans to report its second quarter financial results on August 9, 2022, before the market opens. The company is focused on developing Red Cell Therapeutics™, innovative treatments for cancer and autoimmune diseases using its proprietary RED PLATFORM® technology. Notably, the company will not host a teleconference alongside the financial results announcement. Rubius has received accolades, being recognized as a top workplace in Massachusetts and Rhode Island.
- Rubius is advancing innovative Red Cell Therapeutics™ for cancer and autoimmune diseases.
- The company has been recognized as one of the top workplaces in Massachusetts.
- No teleconference will be held to discuss the financial results, potentially reducing investor engagement.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.
The company will not be hosting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Investors
Lori Murray, Chief Corporate Affairs Officer
lori.murray@rubiustx.com
Media
Marissa Hanify, Director, Corporate Communications
marissa.hanify@rubiustx.com
FAQ
When will Rubius Therapeutics report its second quarter financial results?
What is Rubius Therapeutics focusing on?
Why is Rubius Therapeutics not hosting a teleconference for its earnings report?
What is the key technology used by Rubius Therapeutics?
